Skip to main content
Premium Trial:

Request an Annual Quote

Funding Update: Dec 24, 2010

Premium

Recent NSF Awards in Proteomics and Protein Research

Title: A Toolbox for Protein Sample Pretreatment
Principal Investigator: Frank Jahnke
Sponsor: Sonata Biosciences
Start/End Date: Jan. 1, 2011 – June 30, 2011
Amount Awarded to Date: $150,000

Funds work to test the feasibility of a “toolbox” designed to pretreat complex protein samples to prepare them for proteomic analysis. The platform allows sequential manipulation of the initial samples without need for physical transfer from one operation to the next, potentially increasing reliability of the sample-prep process while decreasing sample loss and risk of contamination.


Title: Novel Microarray Platforms for Detection of Rare Molecules in Complex Mixtures
Principal Investigator: Michael Harvey
Sponsor: Maine Manufacturing
Start/End Date: Jan. 1, 2011 – June 30, 2011
Amount Awarded to Date: $149,499

Funds the development of a microarray with high protein binding capability to improve fluorescence detection. By using a nitrocellulose membrane modified by functional silanes to allow covalent coupling of proteins and nucleic acids, the researchers hope to create conditions where the capture molecules can be immobilized at a sufficient density to provide a sensitive assay surface.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.